Trends and perspectives in the development of antidiabetic drugs for type 2 diabetes mellitus

Soo Hyun Lee, Jong Keun Lee, Ik Hwan Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Type 2 Diabetes Mellitus, a chronic metabolic disorder which results from a high blood glucose level, is one of the most prevalent and costly diseases of our time. Considering increasing rates of obesity and the aging population in Korea, the number of diabetic patients is likely to rise rapidly in the future. There are five conventional diabetic drugs which work through different mechanisms; sulfonylureas, biguanide, meglitinide, alpha-glucosidase inhibitors, and thiazolidinedione. Although they all have antidiabetic effects, some side effects such as hypoglycemia, weight gain and gastrointestinal intolerance are associated with them. Incretin based therapies, utilizing glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have a lower risk of adverse side effects, have recently been introduced. At present PPAR-targeting drugs are being actively developed. In this research review, particular emphasis has been placed on the current trends and possible biological targets for the new generation of antidiabetic drugs.

Original languageEnglish
Pages (from-to)180-185
Number of pages6
JournalKorean Journal of Microbiology and Biotechnology
Volume40
Issue number3
DOIs
Publication statusPublished - 2012 Sep 1

Fingerprint

Hypoglycemic Agents
Type 2 Diabetes Mellitus
Dipeptidyl-Peptidase IV Inhibitors
Biguanides
Incretins
Peroxisome Proliferator-Activated Receptors
Glucagon-Like Peptide 1
Drug Delivery Systems
Korea
Hypoglycemia
Weight Gain
Blood Glucose
Obesity
Research
Pharmaceutical Preparations
Population
Therapeutics
meglitinide
2,4-thiazolidinedione
Glycoside Hydrolase Inhibitors

Keywords

  • Antidiabetic drugs
  • Incretin therapy
  • Type 2 diabetes

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Microbiology

Cite this

Trends and perspectives in the development of antidiabetic drugs for type 2 diabetes mellitus. / Lee, Soo Hyun; Lee, Jong Keun; Kim, Ik Hwan.

In: Korean Journal of Microbiology and Biotechnology, Vol. 40, No. 3, 01.09.2012, p. 180-185.

Research output: Contribution to journalArticle

@article{4be035b4e4fd488aa969c7225dc10463,
title = "Trends and perspectives in the development of antidiabetic drugs for type 2 diabetes mellitus",
abstract = "Type 2 Diabetes Mellitus, a chronic metabolic disorder which results from a high blood glucose level, is one of the most prevalent and costly diseases of our time. Considering increasing rates of obesity and the aging population in Korea, the number of diabetic patients is likely to rise rapidly in the future. There are five conventional diabetic drugs which work through different mechanisms; sulfonylureas, biguanide, meglitinide, alpha-glucosidase inhibitors, and thiazolidinedione. Although they all have antidiabetic effects, some side effects such as hypoglycemia, weight gain and gastrointestinal intolerance are associated with them. Incretin based therapies, utilizing glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have a lower risk of adverse side effects, have recently been introduced. At present PPAR-targeting drugs are being actively developed. In this research review, particular emphasis has been placed on the current trends and possible biological targets for the new generation of antidiabetic drugs.",
keywords = "Antidiabetic drugs, Incretin therapy, Type 2 diabetes",
author = "Lee, {Soo Hyun} and Lee, {Jong Keun} and Kim, {Ik Hwan}",
year = "2012",
month = "9",
day = "1",
doi = "10.4014/kjmb.1205.05012",
language = "English",
volume = "40",
pages = "180--185",
journal = "Korean Journal of Microbiology and Biotechnology",
issn = "1598-642X",
publisher = "Korean Society for Microbiolog and Biotechnology",
number = "3",

}

TY - JOUR

T1 - Trends and perspectives in the development of antidiabetic drugs for type 2 diabetes mellitus

AU - Lee, Soo Hyun

AU - Lee, Jong Keun

AU - Kim, Ik Hwan

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Type 2 Diabetes Mellitus, a chronic metabolic disorder which results from a high blood glucose level, is one of the most prevalent and costly diseases of our time. Considering increasing rates of obesity and the aging population in Korea, the number of diabetic patients is likely to rise rapidly in the future. There are five conventional diabetic drugs which work through different mechanisms; sulfonylureas, biguanide, meglitinide, alpha-glucosidase inhibitors, and thiazolidinedione. Although they all have antidiabetic effects, some side effects such as hypoglycemia, weight gain and gastrointestinal intolerance are associated with them. Incretin based therapies, utilizing glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have a lower risk of adverse side effects, have recently been introduced. At present PPAR-targeting drugs are being actively developed. In this research review, particular emphasis has been placed on the current trends and possible biological targets for the new generation of antidiabetic drugs.

AB - Type 2 Diabetes Mellitus, a chronic metabolic disorder which results from a high blood glucose level, is one of the most prevalent and costly diseases of our time. Considering increasing rates of obesity and the aging population in Korea, the number of diabetic patients is likely to rise rapidly in the future. There are five conventional diabetic drugs which work through different mechanisms; sulfonylureas, biguanide, meglitinide, alpha-glucosidase inhibitors, and thiazolidinedione. Although they all have antidiabetic effects, some side effects such as hypoglycemia, weight gain and gastrointestinal intolerance are associated with them. Incretin based therapies, utilizing glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have a lower risk of adverse side effects, have recently been introduced. At present PPAR-targeting drugs are being actively developed. In this research review, particular emphasis has been placed on the current trends and possible biological targets for the new generation of antidiabetic drugs.

KW - Antidiabetic drugs

KW - Incretin therapy

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84867774450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867774450&partnerID=8YFLogxK

U2 - 10.4014/kjmb.1205.05012

DO - 10.4014/kjmb.1205.05012

M3 - Article

AN - SCOPUS:84867774450

VL - 40

SP - 180

EP - 185

JO - Korean Journal of Microbiology and Biotechnology

JF - Korean Journal of Microbiology and Biotechnology

SN - 1598-642X

IS - 3

ER -